The Turkey pharmaceutical market was valued at USD 10.52 Billion in 2025, benefiting from government initiatives aimed at boosting domestic pharmaceutical manufacturing and R&D capacity. It is expected to grow at a CAGR of 4.00% during the forecast period of 2026-2035 and attain a market value of USD 15.57 Billion by 2035. The market is further driven by increasing access to healthcare and evolving patient needs further support the demand for diverse therapeutic and dosage forms.
Base Year
Historical Period
Forecast Period
Increasing government investment in healthcare infrastructure is expected to enhance domestic pharmaceutical production and distribution capabilities.
Rising prevalence of chronic diseases will continue to drive long-term demand for innovative and affordable pharmaceutical therapies.
Strategic export positioning and regulatory harmonization with the EU may strengthen Turkey’s role as a regional pharma manufacturing hub.
Compound Annual Growth Rate
4%
Value in USD Billion
2026-2035
*this image is indicative*
The pharmaceutical industry in Turkey encompasses the development, manufacturing, and distribution of drugs used for the prevention, diagnosis, and treatment of various medical conditions. It includes both prescription drugs and over-the-counter (OTC) medicines, catering to therapeutic areas such as oncology, cardiovascular diseases, neurology, and respiratory ailments. This diverse therapeutic coverage has enabled pharmaceutical companies to address a wide range of health issues, thereby enhancing market penetration. The market is expected to grow at a CAGR of 4.00% during the forecast period of 2026-2035.
Rising Adoption of Biologics and Biosimilars Driving Market Growth
Biologics are gaining popularity in Turkey, especially in oncology and autoimmune therapy areas. For instance, in January 2024, the Turkish Medicines and Medical Devices Agency approved a new wave of locally manufactured biosimilars to reduce treatment costs and improve accessibility. This shift supports market value by enabling cost-effective treatment and strengthening Turkey’s R&D capabilities.
Growth of E-Pharmacy and Online Sales to Boost Turkey Pharmaceutical Market Demand
Digital transformation in Turkey’s healthcare sector has significantly contributed to the growth of e-pharmacy platforms. Increasing internet penetration, improved digital literacy, and growing consumer preference for convenience have led to a steady rise in online consultations and medicine purchases. This shift is expanding distribution channels for pharmaceutical companies, particularly in chronic disease management and wellness-focused OTC products, supporting market accessibility and patient engagement.
The rising chronic diseases, aging population, and increased domestic R&D investments are amongst the major market trends.
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Molecule Type
Market Breakup by Type
Market Breakup by Mode of Purchase
Market Breakup by Application
Market Breakup by Route of Administration
Market Breakup by End User
Oncology to Lead the Segmentation by Application
The oncology segment is among the fastest-growing areas in the market by application, driven by a rising incidence of cancer. Cancer is currently the third leading cause of death in Turkey, and between 2023 and 2050, it is expected to account for 19% of all premature deaths, those occurring before age 75. Each year, an estimated 48,500 premature deaths are expected to result from cancer, reducing average life expectancy by approximately 1.4 years compared to a scenario without the disease. The segment’s growth is further supported by the introduction of targeted therapies, biologics, and advancements in early screening.
The key features of the market report comprise patent analysis, funding and investment analysis strategic initiatives by the leading players. The major companies in the market are as follows:
As the largest pharmaceutical company in Turkey, Abdi İbrahim plays a pivotal role in the country’s healthcare landscape. The company manufactures a broad portfolio that includes generics, over-the-counter (OTC) products, and biosimilars, aligning with global regulatory standards. Abdi İbrahim has made significant investments in R&D infrastructure, including the AbdiBio biotechnology production facility, which is one of the most advanced in the region.
Deva Holding is one of Turkey’s most prominent pharmaceutical manufacturers, known for its diversified therapeutic portfolio and state-of-the-art EU-GMP-certified production facilities. The company manufactures a wide range of pharmaceutical forms, including injectables, tablets, and ophthalmic products, catering to both prescription and hospital-use segments. Deva’s export network spans Europe, the Middle East, and North Africa, aligning with Turkey’s national strategy to boost pharma exports. Through continuous product development and facility expansion, Deva reinforces its role as a leading player in both domestic and international markets.
Operating as a subsidiary of the global Sanofi Group, Sanofi specializes in key therapeutic areas such as vaccines, diabetes, and cardiovascular diseases. Its Lüleburgaz production facility is one of the largest in the region, playing a central role in supplying not only the Turkish market but also international markets. The company is actively involved in clinical research and academic collaborations, enhancing Turkey’s profile as a clinical trial destination. Sanofi's long-standing presence and commitment to innovation support the development of localized healthcare solutions while ensuring access to advanced global therapies.
Novartis is a global innovation-driven pharmaceutical company with a strong footprint in Turkey, particularly in oncology, immunology, and neurology. Novartis invests significantly in local manufacturing capabilities and collaborates with Turkish stakeholders in the field of digital health and precision medicine. The company supports technology transfer initiatives and participates in strategic partnerships to enhance Turkey’s R&D ecosystem. Novartis’s integrated approach contributes to building a sustainable pharmaceutical infrastructure while accelerating the availability of cutting-edge therapies in the Turkish market.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Pfizer, Bayer, İlko Pharmaceuticals, Amgen, AstraZeneca, and Koçak Farma.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Molecule Type |
|
| Breakup by Type |
|
| Breakup by Mode of Purchase |
|
| Breakup by Application |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share